lifastuzumab vedotin (DNIB0600A) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lifastuzumab vedotin (DNIB0600A) / Roche
NCT01991210 / 2012-005776-34: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Terminated
2
95
US, Canada, Europe
DNIB0600A, RO5541081, PLD
Genentech, Inc.
Ovarian Cancer
08/16
08/16

Download Options